Management of stage I/II hypopharyngeal cancer.
CONCLUSIONS
It is suggested that radiotherapy might be the first choice for stage I/II hypopharyngeal cancer, and that adjuvant treatment might be necessary for stage II patients to prevent distant metastasis.


OBJECTIVE
To update the therapeutic outcome of early hypopharyngeal cancer.


METHODS
Twenty-eight patients with stage I/II hypopharyngeal cancer (8 in stage I, 20 in stage II) were treated at Kyoto University Hospital between 1995 and 2007. Of 8 cases in stage I, radiotherapy was applied for 4 cases, and surgical treatment for another 4, while 13 of 20 cases in stage II underwent radiotherapy and the remaining 7 cases underwent surgery.


RESULTS
The 5-year cumulative disease-specific survival and larynx preservation rates were 74.6% and 73.2%, respectively. Recurrent tumors were found in two cases in stage I treated by surgery and in five cases in stage II treated with radiotherapy. Two of five recurrent cases in stage II were rescued by salvage surgery. Distant metastasis to the lung appeared in two cases in stage II after initial treatment.
Kitamura
Morimasa
M
Department of Otolaryngology Head and Neck Surgery, Kyoto University, Kyoto, Japan. m_kitamura@ent.kuhp.kyoto-u.ac.jp
Hirano
Shigeru
S
Tateya
Ichiro
I
Kada
Shinpei
S
Ishikawa
Seiji
S
Kanda
Tomoko
T
Tanaka
Shinzo
S
Ito
Juichi
J
D000368:Aged; D000369:Aged, 80 and over; D015331:Cohort Studies; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007012:Hypopharyngeal Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D007564:Japan; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010611:Pharyngectomy; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome